Literature DB >> 16863936

Comparison of daily megavoltage electronic portal imaging or kilovoltage imaging with marker seeds to ultrasound imaging or skin marks for prostate localization and treatment positioning in patients with prostate cancer.

Christopher F Serago1, Steven J Buskirk, Todd C Igel, Ashley A Gale, Nicole E Serago, John D Earle.   

Abstract

PURPOSE: To compare the accuracy of imaging modalities, immobilization, localization, and positioning techniques in patients with prostate cancer. METHODS AND MATERIALS: Thirty-five patients with prostate cancer had gold marker seeds implanted transrectally and were treated with fractionated radiotherapy. Twenty of the 35 patients had limited immobilization; the remaining had a vacuum-based immobilization. Patient positioning consisted of alignment with lasers to skin marks, ultrasound or kilovoltage X-ray imaging, optical guidance using infrared reflectors, and megavoltage electronic portal imaging (EPI). The variance of each positioning technique was compared to the patient position determined from the pretreatment EPI.
RESULTS: With limited immobilization, the average difference between the skin marks' laser position and EPI pretreatment position is 9.1 +/- 5.3 mm, the average difference between the skin marks' infrared position and EPI pretreatment position is 11.8 +/- 7.2 mm, the average difference between the ultrasound position and EPI pretreatment position is 7.0 +/- 4.6 mm, the average difference between kV imaging and EPI pretreatment position is 3.5 +/- 3.1 mm, and the average intrafraction movement during treatment is 3.4 +/- 2.7 mm. For the patients with the vacuum-style immobilization, the average difference between the skin marks' laser position and EPI pretreatment position is 10.7 +/- 4.6 mm, the average difference between kV imaging and EPI pretreatment position is 1.9 +/- 1.5 mm, and the average intrafraction movement during treatment is 2.1 +/- 1.5 mm.
CONCLUSIONS: Compared with use of skin marks, ultrasound imaging for positioning provides an increased degree of agreement to EPI-based positioning, though not as favorable as kV imaging fiducial seeds. Intrafraction movement during treatment decreases with improved immobilization.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16863936     DOI: 10.1016/j.ijrobp.2006.04.019

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  18 in total

1.  Phantom measurements to quantify the accuracy of a commercially available cone-beam CT gray-value matching algorithm using multiple Fiducials.

Authors:  Frederick Marc Köhler; Judit Boda-Heggemann; Beate Küpper; Dirk Wolff; Hansjörg Wertz; Frank Lohr; Frederik Wenz
Journal:  Strahlenther Onkol       Date:  2009-02-18       Impact factor: 3.621

2.  Changes in rectal volume and prostate localization due to placement of a rectum-emptying tube.

Authors:  Hiroshi Fuji; Shigeyuki Murayama; Masashi Niwakawa; Raizou Yamaguchi; Ryou Yamashita; Takashi Matsui; Haruo Yamashita; Tetsuo Nishimura; Kenichi Tobisu
Journal:  Jpn J Radiol       Date:  2009-06-25       Impact factor: 2.374

3.  Comparison of prostate positioning guided by three-dimensional transperineal ultrasound and cone beam CT.

Authors:  Minglun Li; Hendrik Ballhausen; Nina-Sophie Hegemann; Michael Reiner; Stefan Tritschler; Christian Gratzke; Farkhad Manapov; Stefanie Corradini; Ute Ganswindt; Claus Belka
Journal:  Strahlenther Onkol       Date:  2016-12-07       Impact factor: 3.621

Review 4.  Fiducial marker guided prostate radiotherapy: a review.

Authors:  Angela G M O'Neill; Suneil Jain; Alan R Hounsell; Joe M O'Sullivan
Journal:  Br J Radiol       Date:  2016-09-23       Impact factor: 3.039

5.  Acute Toxicity in Hypofractionated/Stereotactic Prostate Radiotherapy of Elderly Patients: Use of the Image-guided Radio Therapy (IGRT) Clarity System.

Authors:  Rossella DI Franco; Valentina Borzillo; Domingo Alberti; Gianluca Ametrano; Angela Petito; Andrea Coppolaro; Ilaria Tarantino; Sabrina Rossetti; Sandro Pignata; Gelsomina Iovane; Sisto Perdonà; Giuseppe Quarto; Giovanni Grimaldi; Alessandro Izzo; Luigi Castaldo; Raffaele Muscariello; Marcello Serra; Gaetano Facchini; Paolo Muto
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

6.  Improved human observer performance in digital reconstructed radiograph verification in head and neck cancer radiotherapy.

Authors:  Jared D Sturgeon; John A Cox; Lauren L Mayo; G Brandon Gunn; Lifei Zhang; Peter A Balter; Lei Dong; Musaddiq Awan; Esengul Kocak-Uzel; Abdallah Sherif Radwan Mohamed; David I Rosenthal; Clifton David Fuller
Journal:  Int J Comput Assist Radiol Surg       Date:  2014-12-05       Impact factor: 2.924

7.  Method comparison of automated matching software-assisted cone-beam CT and stereoscopic kilovoltage x-ray positional verification image-guided radiation therapy for head and neck cancer: a prospective analysis.

Authors:  Clifton D Fuller; Todd J Scarbrough; Jan-Jakob Sonke; Coen R N Rasch; Mehee Choi; Joe Y Ting; Samuel J Wang; Niko Papanikolaou; David I Rosenthal
Journal:  Phys Med Biol       Date:  2009-11-24       Impact factor: 3.609

8.  Time and frequency to observe fiducial markers in MLC-modulated fields during prostate IMRT/VMAT beam delivery.

Authors:  Qianqian Xu; Xu Tong; Muhan Lin; Xiaoming Chen; Ahmed ElDib; Teh Lin; Lili Chen; C-M Charlie Ma
Journal:  Phys Med       Date:  2020-07-14       Impact factor: 2.685

9.  Comparison of daily couch shifts using MVCT (TomoTherapy) and B-mode ultrasound (BAT System) during prostate radiotherapy.

Authors:  Steven H Lin; Elizabeth Sugar; Terrance Teslow; Todd McNutt; Habeeb Saleh; Danny Y Song
Journal:  Technol Cancer Res Treat       Date:  2008-08

10.  Tumor motion tracking based on a four-dimensional computed tomography respiratory motion model driven by an ultrasound tracking technique.

Authors:  Lai-Lei Ting; Ho-Chiao Chuang; Ai-Ho Liao; Chia-Chun Kuo; Hsiao-Wei Yu; Hsin-Chuan Tsai; Der-Chi Tien; Shiu-Chen Jeng; Jeng-Fong Chiou
Journal:  Quant Imaging Med Surg       Date:  2020-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.